Subscribe To Our Free Newsletter |
Sun Pharma ends Proseek study due to Vodobatinib failure; Shares down
Sun Pharma said the interim analysis did not meet the pre-specified primary endpoint of change in MDS-UPDRS Part III total score compared to placebo